Overview

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip

Status:
Completed
Trial end date:
2021-06-15
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to describe the safety and tolerability of fasinumab, including adverse events of special interest (AESIs), in patients with pain due to radiographically-confirmed OA of the knee or hip.
Phase:
Phase 3
Details
Lead Sponsor:
Regeneron Pharmaceuticals
Collaborator:
Teva Pharmaceutical Industries, Ltd.
Treatments:
Fasinumab